Abstract 5684: The role of the lncRNA Slamon and Slc25a13 neighbor gene in melanoma aggressiveness

Abstract

Abstract Melanomas are responsible for about 80% of all deaths related to skin cancers. This is due to its high potential of metastasizing and developing resistance to treatments. Novel therapeutic modalities and the identification of biomarkers able to predict the prognosis are necessary. Studies have revealed the central role of long non-coding RNAs (lncRNAs) in regulatory networks controlling cell behavior. The disruption of these regulatory networks as a consequence of altered expression of lncRNAs can contribute to cancer development and progression. Our laboratory has developed a linear cellular model of melanoma progression consisting of distinct cell lines: melan-a (melanocytes), 4C (pre-malignant melanocytes), 4C11- (undifferentiated, slow-growing and non-metastatic melanoma cells) and 4C11+ (differentiated, highly proliferative and metastatic melanoma cells), which were analyzed for their lncRNA expression profile. Differentially expressed lncRNAs identified by RNAseq were selected by in silico analyses based on their proximity to differentially expressed coding-genes in the same melanoma model. Correlation analyses were performed between the expression of differentially expressed lncRNA neighboring genes and their melanoma patient survival, using two independent melanoma cohorts (TCGA and Leeds). Among those lncRNA located near genes presenting prognostic value is the lncRNA Gm20619, here named Slamon, neighbor to Slc25a13 gene (mitochondrial aspartate/glutamate carrier gene), which high expression correlates with poor prognosis. Both Slamon lncRNA and Slc25a13 are highly expressed in the metastatic melanoma cells 4C11+ compared to melan-a, 4C and 4C11- cell lines. The knocking down of Slamon or Slc25a13 were performed in 4C11+ melanoma cells, followed by analyses of collective migration, clonogenicity, proliferation, anoikis resistance, and dacarbazine and MEK inhibitor treatment. By knocking down Slamon lead 4C11+ cells significantly less migratory and less resistant to dacarbazine, and resulted in increased expression of Slc25a13 gene. 4C11+ melanoma cells knocked down for Slc25a13 also presented reduced migratory, clonogenicity, proliferation and anoikis resistance capability, diminished sensitivity to dacarbazine and MEK inhibitor treatment, and increased expression of Slamon lncRNA. The analysis of genes coexpressed with Slc25a13 revealed genes related to tumor progression, as Cdk15, Lsp1 and Pdgfrb. Our results suggest a crucial role of the lncRNA Slamon and Slc25a13 coding gene in melanoma progression which has never been described before. Slamon regulates tumor aggressiveness associated with Slc25a13, forming a regulatory network. These findings reveal the importance of lncRNAs in melanoma biology, potentially indicating transcripts that can serve as prognostic biomarkers and therapeutic targets in melanoma. Citation Format: Beatriz C. Tonin, Ana L. Ayub, André H. Lengert, Sang W. Han, Eduardo M. Reis, Frank J. Slack, Miriam G. Jasiulionis. The role of the lncRNA Slamon and Slc25a13 neighbor gene in melanoma aggressiveness [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5684.